Zevra Therapeutics Inc (FRA:1GDA)
€ 4.14 -0.22 (-4.95%) Market Cap: 173.41 Mil Enterprise Value: 165.56 Mil PE Ratio: 0 PB Ratio: 3.90 GF Score: 50/100

KemPharm Inc at JMP Securities Life Sciences Conference (Virtual) Transcript

Jun 15, 2022 / 04:30PM GMT
Release Date Price: €3.9 (-5.04%)
Jason Butler
JMP Securities - Analyst

Thanks again for joining us now this afternoon at the JMP Securities Life Sciences Conference. Next company we have presenting to us is KemPharm. KemPharm is a biopharma company that has a core platform technology that enables prodrugs, and has a couple approved products on the market on the back of that technology, and is now advancing a pipeline as well.

So, with us today is Rich Pascoe, the company's Exec Chairman. So, Rich, turn it over to you. Thanks.

Rich Pascoe
KemPharm, Inc. - Executive Chairman

Thank you, Jason. And on behalf of our CEO, Travis Mickle, and the entire team at KemPharm, it's good to be here in person and we appreciate JMP inviting us to share our story.

Before I begin my formal remarks, I'll remind you that we will be making certain forward-looking statements, and I would kindly ask you to refer to our 10-Q and K, which are available on our website, kempharm.com, as well as SEC.gov.

KemPharm is a pharmaceutical company focused on the development, and now

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot